Pacira BioSciences Faces Class Action Amid Patent Invalidation

Pacira BioSciences and the Pending Class Action

Pacira BioSciences, Inc. (NASDAQ: PCRX) is currently facing a class action lawsuit that calls the attention of investors. The Gross Law Firm has notified shareholders regarding the implications of this legal situation, particularly after alarming news about the company’s patent.

Understanding the Class Period and Allegations

The timeframe for the class action spans from early August 2023 to early August 2024. The lawsuit relates to the company's patent for Exparel, a key product that substantially contributes to Pacira's revenue, accounting for nearly 80% of its income. Following a court decision on this patent's validity, shareholders may have substantial concerns.

What Happened with the Patent?

On August 9, a significant press release disclosed that a court found Pacira’s U.S. Patent No. 11,033,495 to be invalid. This ruling means that eVenus, a competitor, is not infringing this patent, which creates uncertainties about the future for Pacira BioSciences. The invalidity of this essential patent raises questions about other patents held by the company and may expose the company to increased competition in the market.

Stock Price Reaction

The market responded sharply to the news. Pacira's stock price fell dramatically, from a closing price of $22.36 per share on August 8 to a low of $11.70 on August 9, marking a drastic 47% reduction in a single day. Such a decline reflects investors’ apprehension following the patent ruling, prompting many to consider whether to join the class action suit.

Deadlines and Next Steps for Investors

Shareholders interested in participating in the class action must act soon, as the deadline for registering as a lead plaintiff is March 14, 2025. Engaging with this process could help investors recover losses incurred during the tumultuous period impacted by the court ruling.

Benefits of Registration

Once registered, shareholders will gain access to a comprehensive portfolio monitoring system. This service is designed to provide regular updates throughout the class action proceedings. Importantly, registering comes at no cost to the participant.

Why Choose Gross Law Firm?

The Gross Law Firm has established a reputation as a leading national class action law firm. They focus on upholding the rights of investors who might suffer due to unethical business tactics, including fraud and misrepresentation. Their commitment to protecting shareholders' interests is evident, aiming to recover losses sustained by investors during this turbulent time at Pacira BioSciences.

Contact Information for Shareholders

For those wishing to learn more or seek assistance, the Gross Law Firm is available for inquiries. Their office is located on West 38th Street in New York City. Investors can reach out via the phone for further discussions about the current class action and how to participate. Direct email contact details can be provided upon inquiry.

Frequently Asked Questions

What is the class action lawsuit about?

The lawsuit is focused on allegations related to the invalidation of Pacira's key patent, impacting its stock performance and shareholder rights.

Who is eligible to join the class action?

Shareholders who purchased shares of Pacira BioSciences during the specified class period are encouraged to join.

What are the potential outcomes of the lawsuit?

Investors may have a chance to recover losses depending on the proceedings and eventual outcome of the class action.

Is there a cost to participate in the lawsuit?

No, there is no cost or obligation for shareholders who register to participate in the class action.

How can I stay updated on the lawsuit?

By registering, shareholders will receive updates through a dedicated monitoring system provided by the legal team handling the class action.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.